We recently published a list of Thursday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where ...

Automated three-dimensional total-body photography improves the efficiency of positive malignant biopsies and reduces ...

D-Wave Quantum fell for a third straight day on Thursday, losing 18.02 percent to end at $8.69 each as investors sold off ...

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated ...

H.C. Wainwright lowered the firm’s price target on Alumis (ALMS) to $15 from $19 and keeps a Buy rating on the shares following the Q4 report.

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to ...

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...

Acelyrin (NASDAQ:SLRN) stock in focus as the company adopts a poison pill to counter rapid stock acquisition by Tang Capital Partners. Read more here.

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...